Strong Generics-led finish to 2023
22/02/24 -"Hikma’s H2 23 results exceeded the street’s expectations, with Generics being the lead performer. Even the 2024 guidance was largely in line with the consensus estimates. The results were cheered by ..."
Pages
52
Language
English
Published on
22/02/24
You may also be interested by these reports :
07/08/26
Genmab’s Q2 performance exceeded expectations. The blood cancer drug Darzalex demonstrated strong results, with other drugs also showing solid ...
05/08/26
The Q2 results exceeded expectations, aided by sustained strong uptake for the Wegovy pill (obesity). Consequently, the management upgraded its ...
04/08/26
BioNTech reported a disappointing quarter, with sales significantly below forecasts and operating losses exceeding expectations. Weaker Covid-19 ...
04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...